- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01932671
The SMART-ORACLE Study (SMART-ORACLE)
Optimising Risk Assessment With CT-angiography or Calcium Score in Patients at High Risk for a Cardiovascular Event
Studieöversikt
Status
Detaljerad beskrivning
Patients with a prior cardiovascular event exhibit an elevated risk for subsequent cardiovascular events. The Second Manifestation of Arterial Disease Study (SMART) has recruited over 10,000 patients since 1996 with clinically manifest cardiovascular disease in a multidisciplinary single center study involving primary care physicians, cardiologists, neurologists, vascular surgeons, vascular medicine specialists and radiologists. Within this study a prediction model was developed to accurately estimate the risk for new cardiovascular events. It is now possible to acquire high-quality motion-free computed tomography (CT) images of the coronary and carotid arteries. Imaging biomarkers extracted from these images may further improve the prediction of future manifestations of arterial disease and personalize disease monitoring and medical care.
The SMART-ORACLE study is a prospective, single center, observational cohort study aiming to include 1500 patients. The primary aim is to identify predictors of future cardiovascular events. Eligible patients will be selected via the recruitment of the original SMART study. Patients participating in the SMART-ORACLE study will undergo calcium scoring in multiple cardiovascular beds and contrast-enhanced CT-scans of the coronary and carotid arteries in addition to the regular SMART investigations. Patients with renal dysfunction will be either excluded from the study or will receive pre-hydration (depending on eGFR) to minimize the risk of contrast nephropathy. Follow-up with questionnaire-based assessment will take place every 26 weeks until death of participant or end of the SMART study, asking participants about possible new cardiovascular events. Endpoints will be adjudicated by a committee of three experts. The aim is to collect 170 future events.
The main analysis will consist of Cox proportional hazard analysis. Imaging biomarkers will be added to the existing prediction model to assess their (independent) discriminatory capacity for future events. The c-statistic will be used to measure the discrimination of each model. Net reclassification improvement tables will be constructed to evaluate the added value of imaging markers in terms of reclassification. Based on a one-year-occurrence rate of subsequent cardiovascular events in the current SMART population database of 2.6%, about 6500 person years of follow-up are needed to obtain the adequate number of endpoints.
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studieorter
-
-
-
Utrecht, Nederländerna, 3508 GA
- UMC Utrecht
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- History of cardiovascular event (coronary carter disease, cardiovascular disease, transient ischemic attack, minor stroke peripheral artery disease , abdominal aortic aneurysm)
- Diabetes Mellitus type 2
- Hypertension (Blood pressure>140/90 mm Hg)
Exclusion Criteria:
- Known renal failure (defined as eGFR <46 ml/min/1.73 m2 estimated based on the modification of diet in renal disease (MDRD) formula)
- Previous allergic reaction to contrast, necessitating medical intervention
- Other contra-indication for CT-scanning (e.g. pregnancy, acute hypotension (<100 mm Hg systolic), clinical instability)
- Prior exposure to ionizing radiation for scientific purposes without advantage for the patient
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Kohort
- Tidsperspektiv: Blivande
Kohorter och interventioner
Grupp / Kohort |
---|
SMART
The SMART (Second Manifestation of ARTerial disease) cohort comprises patients at high-risk for or who have clinically manifest cardiovascular disease, including transient ischemic attack, cerebrovascular disease, peripheral artery disease, aneurysma aorta abdominalis, myocardial infarction, coronary ischemia for which coronary intervention is required, renal artery stenosis, diabetes mellitus, hyperlipidemia, hypertension, patients diagnosed with human immunodeficiency virus, pre-eclampsia, HELLP syndrome, abruption placentae and Intrauterine growth restriction in medical history.
Participants are re-invited after 4 years for a second screening.
This screening is performed to study the progression of atherosclerosis and evaluate the effects of the advice of the multidisciplinary team.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Combined endpoint of cardiovascular events
Tidsram: Every 26 weeks until death of participant or end of the SMART study, with an expected average of 15 years
|
(non-fatal) ischemic stroke (non-fatal) myocardial infarction (cardio)vascular death Endpoints will be adjudicated by a committee of three experts.
|
Every 26 weeks until death of participant or end of the SMART study, with an expected average of 15 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Carotid artery intervention
Tidsram: Every 26 weeks until death of participant or end of the SMART study, with an expected average of 15 years
|
Carotid desobstruction or stenting
|
Every 26 weeks until death of participant or end of the SMART study, with an expected average of 15 years
|
Transient ischemic attack
Tidsram: Every 26 weeks until death of participant or end of the SMART study, with an expected average of 15 years
|
Every 26 weeks until death of participant or end of the SMART study, with an expected average of 15 years
|
|
Abdominal aorta aneurysm
Tidsram: Every 26 weeks until death of participant or end of the SMART study, with an expected average of 15 years
|
Non-fatal rupture, stenting or operation of an abdominal aorta aneurysm
|
Every 26 weeks until death of participant or end of the SMART study, with an expected average of 15 years
|
Peripheral artery disease
Tidsram: Every 26 weeks until death of participant or end of the SMART study, with an expected average of 15 years
|
Amputation, percutaneous transluminal angioplasty or stenting due to peripheral artery disease
|
Every 26 weeks until death of participant or end of the SMART study, with an expected average of 15 years
|
Coronary artery intervention
Tidsram: Every 26 weeks until death of participant or end of the SMART study, with an expected average of 15 years
|
Percutaneous coronary intervention, coronary artery bypass graft
|
Every 26 weeks until death of participant or end of the SMART study, with an expected average of 15 years
|
All cause mortality
Tidsram: Every 26 weeks until death of participant or end of the SMART study, with an expected average of 15 years
|
Every 26 weeks until death of participant or end of the SMART study, with an expected average of 15 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Yolanda van der Graaf, Prof. dr., UMC Utrecht
Publikationer och användbara länkar
Allmänna publikationer
- Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol. 1999 Oct;15(9):773-81. doi: 10.1023/a:1007621514757.
- Dorresteijn JA, Visseren FL, Wassink AM, Gondrie MJ, Steyerberg EW, Ridker PM, Cook NR, van der Graaf Y; SMART Study Group. Development and validation of a prediction rule for recurrent vascular events based on a cohort study of patients with arterial disease: the SMART risk score. Heart. 2013 Jun;99(12):866-72. doi: 10.1136/heartjnl-2013-303640. Epub 2013 Apr 10.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Myokardischemi
- Hjärtsjukdom
- Hjärt-kärlsjukdomar
- Kärlsjukdomar
- Störningar i glukosmetabolism
- Metaboliska sjukdomar
- Arterioskleros
- Arteriella ocklusiva sjukdomar
- Sjukdomar i det endokrina systemet
- Åderförkalkning
- Kranskärlssjukdom
- Kranskärlssjukdom
- Diabetes mellitus
- Diabetes mellitus, typ 2
- Perifer arteriell sjukdom
- Perifera vaskulära sjukdomar
Andra studie-ID-nummer
- NL36828.041.11
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Kranskärlssjukdom
-
IRCCS Policlinico S. DonatoRekryteringAnomalous aortic origin of the coronary artery (AAOCA)Italien
-
Biotronik AGAvslutadde Novo Lesions in Native coronary arteriesNederländerna, Schweiz, Tyskland, Belgien
-
University Hospital OstravaRekryteringIn-Stent Carotis Artery RestenosisTjeckien
-
Stanford UniversityIndragenPopliteal Artery Entrapment Syndrome | Funktionell popliteal artery Entrapment SyndromeFörenta staterna
-
Osaka General Medical CenterAvslutadEmergent coronary procedurJapan
-
Sohag UniversityHar inte rekryterat ännuUmblical Artery Doppler under terminsgraviditetEgypten
-
Xiangya Hospital of Central South UniversityWest China Hospital; Henan Provincial People's Hospital; Renmin Hospital... och andra samarbetspartnersRekryteringSpontan isolerad Superior Mesenteric Artery DissektionKina
-
Inova Health Care ServicesBoston Scientific CorporationAvslutadKoronar angiografi | Transradiell åtkomst | Radiell artär Intimal mediala tjocklek | Distal Radial Artery Access (dTRA)Förenta staterna
-
University Hospital, AngersRekryteringPopliteal artär infångningFrankrike
-
Baylor College of MedicineAvslutadLungblödning | MAPCA - Major Aortopulmonary Collateral ArteryFörenta staterna